Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 345

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist

Open access
Yamamura, Yoshitaka, Ogawa, Hidenori, Yamashita, Hiroshi, Chihara, Tomihiko, Miyamoto, Hisashi, Nakamura, Shigeki, Onogawa, Toshiyuki, Yamashita, Tatsuya, Hosokawa, Tetsumi, Mori, Toyoki, Tominaga, Michiaki, Yabuuchi, Youichi·1992·British Journal of Pharmacology

Abstract

OPC‐31260, a benzazepine derivative, has been studied for its ability to antagonize the binding of arginine vasopressin (AVP) to receptors in rat liver (V 1) and kidney (V 2) plasma membranes, for antagonism of the antidiuretic action of AVP in alcohol‐anaesthetized rats and for diuretic action in conscious normal rats. OPC‐31260 caused a competitive displacement of [3 H]‐AVP binding to both V 1 and V 2 receptors with IC 50 values of 1.2 ± 0.2 × 10−6 m and 1.4 ± 0.2 × 10−8 m, respectively. OPC‐31260 at doses of 10 to 100 μg kg−1, i.v., inhibited the antidiuretic action of exogenously administered AVP in water‐loaded, alcohol‐anaesthetized rats in a dose‐dependent manner. OPC‐31260 did not exert an antidiuretic activity suggesting that it is not a partial V 2 receptor agonist. After oral administration at doses of 1 to 30 mg kg−1 in normal conscious rats, OPC‐31260 dose‐dependently increased urine flow and decreased urine osmolality. The diuretic action of OPC‐31260 was characterized as aquaresis, the mode of diuretic action being different from previously known diuretic agents such as furosemide, hydrochlorothiazide and spironolactone. The results indicate that OPC‐31260 is a selective V 2 receptor antagonist and behaves as an aquaretic agent. OPC‐31260 will be a useful tool in studying the physiological role of AVP and in the treatment of various conditions characterized by water retention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.1992.tb09058.x

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 345

Metadata

Authors
Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Onogawa, T., Yamashita, T., Hosokawa, T., Mori, T., Tominaga, M., & Yabuuchi, Y.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
1992-04
Volume
105
Issue
4
Pages
787-791
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2057640040
Cited by
345
References
13
FWCI
19.10
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. https://app.cochat.ai/papers/10.1111/j.1476-5381.1992.tb09058.x
The paper
Yamamura, Y., Ogawa, H., Yamashita, H., Chihara, T., Miyamoto, H., Nakamura, S., Onogawa, T., Yamashita, T., Hosokawa, T., Mori, T., Tominaga, M., & Yabuuchi, Y. (1992). Characterization of a novel aquaretic agent, OPC‐31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.1992.tb09058.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.